KLAREX Health® is a product of Vanessa Research, a U.S., Connecticut-based biomedical company founded on the desire to “give hope where none existed” by making an impact on healthcare markets that are often overlooked. Vanessa Research’s continually expanding pipeline of innovative pharmaceuticals, medical devices, and consumer and public health products reflects the company’s inventive nature and commitment to delivering solutions that increase access to quality care. The company’s flagship products, Shylicine™ and Hunazine™, are the first-ever drugs developed to treat the rare, lethal microvillus inclusion disease and to neutralize the cholera toxin, respectively.
In response to the overwhelming demand for, and market shortage of personal protective items caused by the COVID-19 pandemic, KLAREX Health® was created when Vanessa Research determined the need to utilize its GMP-certified manufacturing facilities' excess capacity to produce the World Health Organization's recommended formulation for hand sanitizer. KLAREX Health® is currently distributed in the three primary regions in which Vanessa Research maintains a physical presence: the United States, Hungary and Spain.
With KLAREX Health®, our hope is to deliver a fairly-priced, effective and critically-important product for the health and safety of the public during this challenging time.
Read more about Vanessa Research Holdings, Inc.